KDMN Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 jan 1970 @ 01:00):

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases...

Stats
Dagens volum	10.42M
Gjennomsnittsvolum	10.03M
Markedsverdi	0.00
EPS	$-0.200 ( 2021-11-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.32
ATR14	$0.213 (2.24%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-09	Waksal Harlan	Sell	177 945	Common Stock
2021-11-09	Waksal Harlan	Buy	655 000	Stock Appreciation Right
2021-11-09	Waksal Harlan	Buy	982 500	Performance Stock Option(right to buy)
2021-11-09	Waksal Harlan	Buy	1 350 000	Stock Option (right to buy)
2021-11-09	Waksal Harlan	Buy	2 000 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 93 transactions
Buy: 16 325 233 \| Sell: 4 159 124

Volum Korrelasjon

Lang: 0.23 (neutral)

Kort: 0.86 (strong)

Signal:(72.9) Same movement expected

Kadmon Holdings Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Kadmon Holdings Inc Korrelasjon - Valuta/Råvare

-0.16
( neutral )

0.62
( weak )

0.51
( weak )

0.09
( neutral )

0.48
( neutral )

0.21
( neutral )

Kadmon Holdings Inc Økonomi

Annual	2020
Omsetning:	$8.29M
Bruttogevinst:	$6.29M (75.86 %)
EPS:	$-0.670

FY	2020
Omsetning:	$8.29M
Bruttogevinst:	$6.29M (75.86 %)
EPS:	$-0.670

FY	2019
Omsetning:	$5.10M
Bruttogevinst:	$3.81M (74.70 %)
EPS:	$-0.480

FY	2018
Omsetning:	$1.40M
Bruttogevinst:	$714 000 (51.15 %)
EPS:	$-0.580

Financial Reports:

No articles found.

Kadmon Holdings Inc

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.